President Donald Trump signed an executive order on April 18, 2026, to speed up research on psychedelic drugs, with podcaster Joe Rogan at his side [1].
The move matters because it could unlock new treatments for veterans and civilians battling severe mental‑health conditions such as post‑traumatic stress disorder, a problem that has long outpaced conventional therapies [1].
In the Oval Office, Trump and Rogan watched the signing of the order, which directs federal agencies to prioritize funding and regulatory pathways for clinical trials of psychedelics that show promise for treating depression, anxiety, and PTSD [1]—a shift that signals a broader governmental openness to alternative therapies.
The Hill reports that the order calls for “accelerating research for certain psychedelic drugs” without naming a specific compound, while the New York Post notes that ibogaine, a plant‑derived hallucinogen used abroad, is singled out for study [1][2]. By highlighting ibogaine, the Post adds a concrete target to an otherwise broad mandate, suggesting that the administration may allocate resources to a drug already in limited clinical use overseas.
Rogan said, “Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives,” [1]. Trump said, “I’d like some for anxiety,” [4]. Both comments underscore the political and cultural momentum behind re‑examining psychedelics after decades of prohibition.
The order also instructs the National Institutes of Health and the Department of Veterans Affairs to develop a coordinated research agenda, potentially fast‑tracking grant approvals and streamlining Institutional Review Board processes [1]. If successful, the initiative could produce data that inform FDA decisions and expand treatment options for the estimated 20 % of veterans who experience PTSD [3].
What this means: The executive order represents a rare convergence of entertainment media influence and federal policy, aiming to legitimize psychedelic research that has lingered on the fringes of mainstream medicine. By targeting veterans and emphasizing rapid regulatory pathways, the administration hopes to generate clinical evidence that could shift prescribing practices and insurance coverage, potentially changing the therapeutic landscape for millions of Americans suffering from mental‑health disorders.
“Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives.”
The executive order marks a significant policy pivot that could accelerate scientific validation of psychedelics, especially ibogaine, and pave the way for new, federally backed treatment options for mental‑health disorders.
